Avail a Doctor Loan on Bajaj Markets at Affordable Interest Rates

August 21, 2023 03:55 PM AEST | By Businesswire India

Google News:

Avail a Doctor Loan on Bajaj Markets at Affordable Interest Rates — Image source: Businesswire India

Recent News

Sectigo Expands APAC Leadership as Industry Prepares for 47-Day SSL/TL...

LIVE FEED: DISNEY CEO BOB IGER TO RING NYSE OPENING BELL FROM DISNEYLA...

Health In Tech Supports Foster Closet to Help Children and Families in...

Pantalones Drops in New Zealand

Business Wire India

Doctors and medical professionals can now apply for a doctor loan on Bajaj Markets, a subsidiary of Bajaj Finserv. With offers that go up to Rs. 45 Lakhs, one can enjoy affordable interest rates and get funds hassle-free.

Doctors can use the loan amount to:

Purchase new equipment
Upgrade existing medical equipment
Renovate the clinic or hospital
Meet working capital requirements
Hire staff

On Bajaj Markets, doctors can avail doctor loans effortlessly and enjoy various benefits. Here are a few:

Quick and hassle-free application process
Easy-to-meet eligibility criteria and minimal documentation
Pocket-friendly interest rates starting from 14% p.a.
Flexible repayment tenures ranging up to 84 months
Transparent process without any hidden costs involved
Quick disbursement timelines

Bajaj Markets simplifies loan processing by offering a simple online application process. Individuals can also access a range of other financial offerings on the platform. To get started, simply visit the official website or download the app.

To keep reading, please log in to your account, create a free account, or simply fill out the form below.

Send OTP Resend OTP in 30s

By submitting your details above and clicking on the 'Read Now' button, you confirm that you are happy for one of the representatives of Kalkine Media or its group entities to contact you to discuss the services, consent to - our Terms & Conditions, and to receive marketing offers, including to be contacted by email or phone, as set out in our Privacy Policy. Any calls will be made by Kalkine group's telemarketing entities on our behalf or on behalf of Kalkine group entities.

Kalkine Media dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Section 1.10.32 of "de Finibus Bonorum et Malorum", written by Cicero in 45 BC

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium do Kalkine que laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui do Kalkine Media quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt ut labore et dolore magnam aliquam quaerat voluptatem. Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur? Quis autem vel eum iure reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui do Kalkine eum fugiat quo voluptas nulla pariatur?

1914 translation by H. Rackham

But I must explain to you how all this mistaken idea of denouncing pleasure and praising pain was born and I will give you a complete account of the system, and expound the actual teachings of the great explorer of the truth, the master-builder of human happiness. No one rejects, dislikes, or avoids pleasure itself, because it is pleasure, but because those who do not know how to pursue pleasure rationally encounter consequences that are extremely painful. Nor again is there anyone who loves or pursues or desires to obtain pain of itself, because it is pain, but because occasionally circumstances occur in which toil and pain can procure him some great pleasure. To take a trivial example, which of us ever undertakes laborious physical exercise, except to obtain some advantage from it? But who has any right to find fault with a man who chooses to enjoy a pleasure that has no annoying consequences, or one who avoids a pain that produces no resultant pleasure?

1914 translation by H. Rackham

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

CSL (ASX:CSL) and Pro Medicus (ASX:PME): Healthcare Innovators Shaping the ASX 100 Landscape
16, July, 2025
ResMed (ASX:RMD): ASX 100 Healthcare Leader Signals Solid Growth in 2025
16, July, 2025
Mesoblast (ASX:MSB) Insider Confidence Stands Out Amid ASX 300 Landscape
16, July, 2025
Imugene (ASX:IMU) Secures Capital to Accelerate Clinical Trials for Innovative CAR-T Therapy
16, July, 2025
Prescient Therapeutics (ASX:PTX) Begins US Enrolment for PTX-100 Trial | ASX 300
16, July, 2025
Lumos Diagnostics (ASX:LDX) Secures Major US Deal for FebriDx® | All Ordinaries
16, July, 2025
Tryptamine Therapeutics Expands Psilocin Clinical Team Ahead of TRP-8803 Trial | All Ordinaries
16, July, 2025
Tryptamine Therapeutics Advances Psychedelic Research with Key Appointments | ASX200 Clinical Innovation Update
16, July, 2025
Imugene Bolsters Clinical Trial Funding with Capital Raise | ASX200 Pipeline Progress
16, July, 2025
Prescient Therapeutics Extends SPP Timeline | ASX 300 Biotech Eyes PTX-100 Progress
15, July, 2025

View All

Markets

Related Articles

Sponsored Articles

1

2

3

4

5

Investing Ideas

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27